Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03854656
Other study ID # NNF17OC0027822
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 25, 2019
Est. completion date March 2, 2022

Study information

Verified date March 2022
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to investigate effects of 12 weeks time-restricted eating on behaviour and metabolism in individuals with overweight or obesity at high risk of type 2 diabetes.


Description:

Overweight and obese individuals with pre-diabetes or with a family history of diabetes or cardiovascular disease (CVD) are at high risk for developing type 2 diabetes (T2D) and CVD. Current prevention and treatment of obesity and T2D include energy restricted diets and increased levels of physical activity; however, adequate adherence to such strategies is difficult, and maintenance is challenging for most individuals, which stresses the need for feasible and sustainable interventions. Circadian rhythms of behaviour and metabolism are closely related to the daily light/dark cycle and sleep-wake patterns and timing of food intake and fasting periods may affect the circadian rhythms of metabolic organs. In an evolutionary perspective, the pattern of food consumption has been characterised by periods of caloric intake when food was available and subsequent periods of fasting 9. This cyclic pattern leads to cycles of absorption and storage of energy and utilisation of the energy for e.g. tissue repair, stress resistance and vitality where expression of metabolic regulators coordinates with cellular processes, leading to efficient metabolism 10. Factors including the 24-hour availability of energy-dense foods, busy time schedules, different eating and sleep patterns during weekdays and weekends (i.e. 'social jetlag') challenge the feeding-fasting paradigm. Recent data suggest that an erratic diurnal eating pattern characterised by food intake largely spread throughout hours awake (≥15 h) and a concomitant short fasting period is highly prevalent in humans and animal suggest that circadian misalignment of food intake is associated with adverse metabolic effects. A number of animal studies and a few small studies in humans have reported promising effects of time-restricted eating (TRE), without concomitant dietary restrictions, on body weight and other cardiometabolic risk factors. There is a lack of randomized controlled trials investigating effect of TRE in individuals at high risk of type 2 diabetes and cardiovascular diseases. The aim of the present study is to investigate effects of 12 weeks TRE on behaviour and metabolism in individuals with overweight or obesity at high risk of type 2 diabetes. Maintenance will be assessed at a follow-up visit 13 weeks after completion of the trial (26 weeks). Testing will be conducted at baseline and after 6, 12, and 26 weeks. Participants are instructed to follow randomization during one week assessment periods after testing at 6 and 12 weeks. Therefore, the total duration of the intervention is 13 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date March 2, 2022
Est. primary completion date March 2, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - BMI =30 kg/m2 or BMI =25 kg/m2 in combination with pre-diabetes (HbA1c =39-<48 mmol/mol) - Habitual eating/drinking window =12 hours (including foods/snacks and energy containing beverages e.g. soft drinks (except of water)) and an eating/drinking window of =14 hours minimum one day per week Exclusion criteria - Daily smoking - For women: pregnancy, planned pregnancy (within the study period) or lactating - Frequent travels over time zones (max one return trip/travel over times zones (?one hour time difference) during the 13 weeks intervention). - Shift work or partner engaged in shift work (if it affects the person's sleep and eating pattern) - Unable to understand the informed consent and the study procedures - Self-reported history of an eating disorder during the past three years - Self-reported weight change (>5 kg) within three months prior to inclusion - Diabetes - HbA1c =48 mmol/mol - Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, gastrointestinal or psychiatric disease; diabetes or other endocrine disease; immunosuppression - Current treatment with medication or medical devices which significantly affect glucose metabolism, appetite, or energy balance - Current treatment with antidepressants - Bariatric surgery - Implanted or portable electro-mechanical medical device such as a cardiac pacemaker, defibrillator or infusion pump - Celiac disease, Crohn's disease, ulcerative colitis or proctitis - Alcohol/drug abuse or in treatment with disulfiram at time of inclusion - Concomitant participation in other intervention studies - Not able to eat =85% of the test meal because of e.g. allergy Specific exclusion criteria for participants receiving SmartPillTM (n=60) - Gastrointestinal symptoms or diseases such as regular (weekly) abdominal pain, dysphagia, gastric bezoars, strictures, fistulas, bowel obstructions or diverticulitis - Current treatment with medication or medical devices which significantly affect gastrointestinal motility or transit time (prokinetics, antidiarrheals, laxatives, or opioids) - Gastrointestinal surgery within 3 months before inclusion

Study Design


Intervention

Other:
Time-restricted eating
Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles: The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.

Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Gentofte

Sponsors (6)

Lead Sponsor Collaborator
Kristine Færch Aalborg University Hospital, IMotions A/S, Salk Institute for Biological Studies, University of Copenhagen, University of Leeds

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in body weight (kg) Measured in fasted state on a digital scale Change from baseline to the end of the intervention (after 12 weeks)
Secondary Body weight (kg) Measured on a digital scale Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Body mass index (kg/m^2) Calculated from body weight (kg) and height (m) Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Fat mass (kg) Measured by Dual-energy X-ray Absorptiometry Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Fat free mass (kg) Measured by Dual-energy X-ray Absorptiometry Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Fat percentage (%) Measured by Dual-energy X-ray Absorptiometry Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Waist circumference (cm) Measured using tape measure Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Hip circumference (cm) Measured using tape measure Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary HbA1c (mmol/mol and %) Assessed from blood samples at all visits Changes from baseline. All four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Systolic blood pressure (mmHg) Measured under resting and fasting conditions Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Diastolic blood pressure (mmHg) Measured under resting and fasting conditions Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Heart rate (bpm) Measured under resting and fasting conditions during measurements of blood pressure and in the supine position by a handheld ECG measuring device (Vagus™) Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Resting energy expenditure (kcal/day) Measured by indirect calorimetry under resting and fasting conditions Changes from baseline. Measured at visits at baseline and after 12 weeks
Secondary Substrate oxidation (respiratory exchange ratio) Measured by indirect calorimetry under resting and fasting conditions Changes from baseline. Measured at visits at baseline and after 12 weeks
Secondary Metabolites Fasting and postprandial (after a standard mixed breakfast meal) concentrations of metabolites including but not limited to: glucose, lipids, cholesterol, free-fatty acids, and amino acids Changes from baseline. Measured in the blood in the fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test (4 hours) at baseline and end of the intervention (after 12 weeks)
Secondary Hormones Fasting and postprandial (after a standard mixed breakfast meal) concentrations of hormones related to regulation of appetite, glucose and lipid metabolism (including but not limited to: insulin, glucagon, ghrelin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), leptin, fibroblast growth factor 19 (FGF-19), fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15)). Changes from baseline. Measured in the blood in the fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test (4 hours) at baseline and end of the intervention (after 12 weeks)
Secondary Circulating proteins that associate with low-grade inflammation and lipid metabolism Fasting levels of circulating proteins that associate with low-grade inflammation and lipid metabolism. Such proteins are captured by mass-spectrometry driven analyses of the plasma proteome i.e. proteins circulating in the blood Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Respiratory and glycolytic capacities of isolated peripheral blood mononuclear cells (PBMCs) Measured using the Seahorse method, which measures mitochondrial respiration Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Heart rate response to standing up from the supine position Measured by a handheld ECG measuring device (Vagus™). Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)
Secondary Heart rate response to inhalation and exhalation Measured by a handheld ECG measuring device (Vagus™). Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)
Secondary Heart rate response to forced exhalation during rest (valsalva maneuver) Measured by a handheld ECG measuring device (Vagus™). Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)
Secondary Gastric emptying time (hours and minutes) Measured using the SmartPill™ technique. The SmartPill™ is ingested together with a standard mixed breakfast meal Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).
Secondary Small bowel transit time (hours and minutes) Measured using the SmartPill™ technique. The SmartPill™ is ingested together with a standard mixed breakfast meal Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).
Secondary Large bowel transit time (hours and minutes) Measured using the SmartPill™ technique. The SmartPill™ is ingested together with a standard mixed breakfast meal Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).
Secondary Total gastrointestinal transit time (hours and minutes) Measured using the SmartPill™ technique. The SmartPill™ is ingested together with a standard mixed breakfast meal Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).
Secondary Motility index Calculated based on amplitudes and number of contractions measured using the SmartPill™ technique. The SmartPill™ is ingested together with a standard mixed breakfast meal Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).
Secondary Attention measured using eye tracking Eye tracking metrics including gaze duration bias, gaze direction bias, fixations, saccades, pupil size/dilation, distance to screen, ocular vergence and blinks to measure attention in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Emotions measured using facial expression analyses Facial expression analyses using computer-vision algorithms (AFFDEX) to measure emotions in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire Changes from baseline. Fasted state at all four visits (baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Arousal measured using galvanic skin response Changes in conductivity of the skin (galvanic skin response) in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Food choice Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Implicit wanting Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time. Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Explicit liking Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale) Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Explicit wanting Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Insulin sensitivity (indices) Including but not limited to the Matsuda index At all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Insulin resistance (indices) Including but not limited to Homeostaic Model Assessment for Insulin Resistance (HOMA-IR) At all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Subjective appetite Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have nerver been this hungry before". Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)
Secondary Mean amplitude of glycaemic excursions (MAGE) Measured using continous glucose monitoring Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Continuous overall net glycaemic action (CONGA) Measured using continous glucose monitoring Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L) Measured using continous glucose monitoring. Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Mean glucose concentrations Measured using continous glucose monitoring. Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Standard deviation of glucose concentrations Measured using continous glucose monitoring. Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Variation coefficients of glucose concentrations Measured using continous glucose monitoring. Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Physical activity (time spent at different intensities) Sedentary time, light, moderate and vigorous intensity physical activity. Assessed from 24 h/day accelerometry Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Physical activity (counts/min) Assessed from 24 h/day accelerometry Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Physical activity energy expenditure (kcal/day) Assessed from 24 h/day accelerometry Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Physical activity (MET hours) Assessed from 24 h/day accelerometry Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Timing of physical activity (hh:mm) Assessed from activity logs and 24 h/day accelerometry Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Energy intake (kcal/day) Assessed from diet records Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks
Secondary Macronutrient intake (energy percentage) Assessed from diet records Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks
Secondary Timing of dietary intake (hh:mm) Assessed from diet records Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks
Secondary Sleep timing (hh:mm) Including bedtime, sleep onset, wake-up, time out of bed, sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Sleep duration (min) Assessed from sleep logs and 24 h/day accelerometry Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Sleep variability (min) Variability in bedtime, wake-up, sleep duration and sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Sleep onset latency (min) Assessed from sleep logs and 24 h/day accelerometry Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Sleep efficiency (%) Assessed from 24 h/day accelerometry Changes from baseline. Measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Wakefulness (min) Assessed from 24 h/day accelerometry Changes from baseline. Measured for 7 days after the test days at baseline and after 6 and 12 weeks
Secondary Self-reported gastrointestinal symptoms (part 1) Assessed from the questionnaires the Gastrointestinal Symptom Rating Scale (GSRS). Rated on 7-point likert scales. Range: 1 = absence of symptoms to 7 = very severe symptoms. Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported gastrointestinal symptoms (part 2) Assessed from the Gastrointestinal Symptom Score (PAGI-SYM). Rated on 6-point likert scales. Range: 1 = absence of symptoms to 6 = very severe symptoms. Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported gastrointestinal symptoms (part 3) Number of symptoms. Assessed from logs. Changes from baseline. Registered 7 days after the test days at baseline and after 12 weeks
Secondary Self-reported autonomic symptoms Assessed from the questionnaire COMPASS31 Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported control over eating Assessed from the questionnaire Control over Eating Questionnaire Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported sleepiness Assessed from the questionnaire the Epworth Sleepiness Scale Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported sleep quality Assessed from the questionnaire Pittsburgh Sleep Quality Index Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported chronotype Assessed from the Munich Chronotype Questionnaire Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported physical activity Assessed from questionnaire International Physical Activity Questionnaire Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported overall health and wellbeing Assessed from the questionnaire Self-reported health (SF-36 health survey) Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported eating behavior Assessed from The Dutch Eating Behavior Questionnaire Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Self-reported night eating Assessed from The Night Eating Questionnaire Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)
Secondary Daily eating/drinking window (hh:min) Time of first and last meal/beverage Registrered every day (13 weeks intervention and 13 weeks follow-up period)
Secondary Microbiome content and diversity Determined from stool samples. Bacterial DNA and RNA will be purified from the stool samples and changes in the microbiome composition and function will be estimated based on sequencing of the microbiomes' DNA and RNA. Includes but is not limited to the Firmicute/Bacteroidete ratio. Changes from baseline. Collected before or during test days at visits at baseline and after 12 weeks
Secondary Motivation for participation (qualitative methods) Themes and aspects related to motivation for participation will be assessed based on interviews with the participants including completers and potential drop-outs. Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.
Secondary Feasibility of the intervention (qualitative methods) Themes and aspects related to feasibility of the intervention will be assessed based on interviews with the participants including completers and potential drop-outs. Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.
Secondary Satisfaction with the intervention (qualitative methods) Themes and aspects related to satisfaction with the intervention will be assessed based on interviews with the participants including completers and potential drop-outs. Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A